precision oncology
It also announced its collaboration with an unnamed liquid biopsy company.
The lab will be providing drug testing platform services to oncologists and pharmaceutical firms.
The roughly three-year-old company says it now has a post-money valuation over $1 billion.
A interview with Prof Yasushi Goto, Department of Thoracic Oncology, National Cancer Center Hospital, Japan.
The companies' partnership is yet another example of real-world data analysis coming to clinical trials.
Although still far from being tested in humans, the technology could serve as a replacement to blood draws.